Author/Creator: Chu, Myron - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Chu, Myron

1. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Issue 2 (3rd March 2020)

Authors:: Tanaka, Yoshiya; Bass, Damon; Chu, Myron; Egginton, Sally; Ji, Beulah; Roth, David
Journal:: Modern rheumatology
Issue:: Volume 30:Issue 2(2020)
Page Start:: 313
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Issue 3 (4th May 2019)

Authors:: Tanaka, Yoshiya; Bass, Damon; Chu, Myron; Egginton, Sally; Ji, Beulah; Struemper, Herbert; Roth, David
Journal:: Modern rheumatology
Issue:: Volume 29:Issue 3(2019)
Page Start:: 452
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Issue 3 (2nd January 2018)

Authors:: Zhang, Fengchun; Bae, Sang-Cheol; Bass, Damon; Chu, Myron; Egginton, Sally; Gordon, David; Roth, David A; Zheng, Jie; Tanaka, Yoshiya
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77:Issue 3(2018)
Page Start:: 355
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. Issue 2 (2nd July 2021)

Authors:: Tanaka, Yoshiya; Bae, Sang-Cheol; Bass, Damon; Curtis, Paula; Chu, Myron; DeRose, Kathleen; Ji, Beulah; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A
Journal:: RMD open
Issue:: Volume 7:Issue 2(2021)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. Issue 1 (15th April 2022)

Authors:: Zhang, Fengchun; Zheng, Jie; Li, Yang; Wang, Guochun; Wang, Mingjun; Su, Yin; Gu, Jieruo; Li, Xingfu; Bass, Damon; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A
Journal:: RMD open
Issue:: Volume 8:Issue 1(2022)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗